Please Wait a Moment
X

Articles

21Sep

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

21 Sep, 2020 | Return|

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

World Patient Safety Day 2020

The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...

Read More >

Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

MD Revised Headers on CTS forms

Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...

Read More >

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >